Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23977797 | 0.88 | MEN1 (0.33) | MEN1KMT2APOLBKDM4ETSHR | |
| SCHEMBL12448059 | 0.86 | MEN1 (0.45) | MEN1KMT2APOLBKDM4ETSHR | |
| SCHEMBL12120256 | 0.86 | KDM4E (0.33) | KDM4E | |
| SCHEMBL12028002 | 0.85 | KDM4E (0.42) | MEN1KMT2APOLBKDM4ETSHR | |
| SCHEMBL25567922 | 0.84 | MEN1 (0.31) | MEN1KMT2APOLBKDM4ETSHR | |
| SCHEMBL14920988 | 0.84 | MEN1 (0.41) | MEN1KMT2APOLBKDM4ETSHR | |
| SCHEMBL26711220 | 0.83 | MEN1 (0.31) | MEN1KMT2APOLB | |
| SCHEMBL24701914 | 0.82 | ALDH1A1 (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7079430 | 0.82 | MEN1 (0.40) | MEN1KMT2APOLBKDM4ETSHR | |
| SCHEMBL20438419 | 0.81 | KDM4E (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8298744-B2 | Coating material for photoresist pattern and method of forming fine pattern using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-10-30 | — | — | US | claimed |
| US-20080286684-A1 | COATING MATERIAL FOR PHOTORESIST PATTERN AND METHOD OF FORMING FINE PATTERN USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-11-20 | — | — | US | claimed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024100139-A1 | USE OF IFN-I ACTIVITY AS A BIOMARKER FOR TLR INHIBITOR TREATMENT | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-20240018655-A1 | METHOD OF PRODUCING THIN-FILM | ADEKA CORPORATION (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145822-A1 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | FONDAZIONE TELETHON (IT) | 2023-05-11 | — | — | US | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11377441-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080286684-A1 | COATING MATERIAL FOR PHOTORESIST PATTERN AND METHOD OF FORMING FINE PATTERN USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-11-20 | — | — | US | disclosed |
| US-20080260803-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer | ALLERGAN,INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | ALLERGAN,INC (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | MEN1 1792/4885KMT2A 2433/4885POLB 3343/4885 |
| US-11377441-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | MEN1 148/4885KMT2A 445/4885POLB 653/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | MEN1 1295/4885KMT2A 292/4885POLB 735/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | MEN1 752/4885KMT2A 2941/4885POLB 2036/4885 |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | VEGFA, PTK2, KDR | MEN1 1851/4885KMT2A 1220/4885POLB 2170/4885 |
| US-20240018655-A1 | METHOD OF PRODUCING THIN-FILM | RTF1, GIGYF2, HAO2 | MEN1 933/4885KMT2A 2569/4885POLB 2693/4885 |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | FLT1, JAK1, KDR | MEN1 4086/4885KMT2A 858/4885POLB 2270/4885 |
| US-20230145822-A1 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | PRNP, PPIE, PPIC | MEN1 3669/4885KMT2A 4350/4885POLB 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.